New Drug to Prevent Migraine May Start Working in Days
In this study, researchers found that after injection of a new migraine drug they were working with, patients experienced fewer headache hours for those who were suffering from chronic migraine within three to seven days after the first injection. “Chronic migraine affects about one percent of all adults, yet less than five percent of those people receive a correct diagnosis and appropriate treatment,” said study author Marcelo Bigal, MD, PhD, of Teva Pharmaceuticals in Frazer, Penn., which developed the new drug, called TEV-48125. “Most people who receive preventive medication for chronic migraine stop using them, and one reason for that is the drugs can take a long time to become effective. If these results can be confirmed with larger studies, this could be exciting for people with migraine.” To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
June 29-30, 2017; Germany
2nd International Conference on Spine and Spinal Disorders
July 24-26, 2017; Rome, Italy
The Society of University Neurosurgeons Annual Meeting
July 27-Aug. 3, 2017; South Africa
Washington University/St. Louis Children’s Comprehensive SEEG Course
Aug. 10-12, 2017; St. Louis